Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

448 PRAVASTATIN
Eczema (generalized)
(1993): Krasovec M+, Dermatology 186, 248
Erythema multiforme
Exanthems
Ichthyosis
(2007): Sparsa A+, J Eur Acad Dermatol Venereol 21(4), 549
Lichenoid eruption
(2006): Pua VS+, Australas J Dermatol 47(1), 57
(1998): Keough GC+, Cutis 61, 98
(1997): Anthony JL, Montgomery, AL (from Internet)
(observation)
Lupus erythematosus
Photosensitivity
Pruritus
(1992): Yoshimura N+, Transplantation 53, 94
(1991): Malini PL+, Clin Ther 13, 500
Purpura
Rash (sic) (1–10%)
(1992): Betteridge DJ+, BMJ 304, 1335
(1992): Jungnickel PW+, Clin Pharm 11, 677
(1991): Med Lett Drugs Ther 33, 18
(1991): Crepaldi G+, Arch Intern Med 151, 146
(1991): McTavish D+, Drugs 42, 65
(1991): Raasch RH, Drug Intell Clin Pharm 25, 388
(1990): Hunninghake DB+, Atherosclerosis 85, 81 (3.4%)
Stevens–Johnson syndrome
Toxic epidermal necrolysis
Urticaria
Vasculitis
Mucosal
Stomatitis
Hair
Hair – alopecia
(1999): Oakley A, Hamilton, New Zealand (from Internet)
(observation)
Hair – broken-off patches of scalp hair (greenish)
(1998): Fixler R, Cincinnati, OH (personal communication)
(observation)
Other
Abdominal pain
(2006): Tsigrelis C+, World J Gastroenterol 12(43), 7055
Anaphylactoid reactions/Anaphylaxis
Gynecomastia
(1999): Aerts J+, Presse Med (French) 28, 787
Hypersensitivity
Myalgia/Myositis/Myopathy/Myotoxicity (2.7%)
(2005): Alayli G+, Ann Pharmacother 39(7-8), 1358 (with
colchicine)
(2003): Litt JZ, Beachwood, OH (personal case) (observation)
(2002): Sinzinger H, Wien Klin Wochenschr 114(21), 943
(2002): Wilhelmi M+, Cardiovasc Drugs Ther 16(5), 471
(2001): Rehbein H, Jacksonville, FL (from Internet) (observation)
(1995): Garnett WR, Am J Health Syst Pharm 52(15), 1639
(1992): Schalke BB+, NEnglJMed327, 649
Porphyria cutanea tarda
(1994): Perrot JL+, Ann Dermatol Venereol (French) 121, 817
Rhabdomyolysis
(2007): Schindler C+, Clin Ther 29(1), 172
(2006): Biggs MJ+, J Heart Lung Transplant 25(3), 356
(2005): Andrejak M+, Therapie 60(3), 299
(2004): Graham DJ+, JAMA 292(21), 2585 (low risk)
(2002): Cohen LH, Ned Tijdschr Geneeskd 146(9), 440
(2002): Sica DA+, Am J Geriatr Cardiol 11(1), 48
(2002): Sica DA+, Curr Opin Nephrol Hypertens 11(2), 123
(2002): Wilhelmi M+, Cardiovasc Drugs Ther 16(5), 471
(2001): Borrego FJ+, Nefrologia 21(3), 309
(1999): Takei A+, Psychiatry Clin Neurosci 53(4), 539
(1998): Kamiuchi K+, Nihon Rinsho Meneki Gakkai Kaishi
21(1), 48
(1996): Ballantyne CM+, Am J Cardiol 78(5), 532
(1996): Hino I+, Arthritis Rheum 39(7), 1259
(1995): Farmer JA+, Baillieres Clin Endocrinol Metab 9(4), 825
(1995): Garnett WR, Am J Health Syst Pharm 52(15), 1639 (with
either cyclosporine, erythromycin, gemfibrozil or niacin)
(1995): Rosenberg AD+, Anesth Analg 81(5), 1089
(1993): Decoulx E+, Ann Cardiol Angeiol (Paris) 42(5), 267
(1992): Raimondeau J+, Presse Med 21(14), 663 (with
fenofibrate)
PRAZEPAM
Trade names: Centrax; Demetrin; Lysanxia; Prazene; Sedapran;
Trepidan
Indications: Anxiety, depression
Category: Benzodiazepine
Half-life: 30–100 hours
Skin
Dermatitis (1–10%)
Diaphoresis (>10%)
Exanthems
Facial edema
Peripheral edema
Pruritus
Purpura
Rash (sic) (>10%)
Urticaria
Mucosal
Gingivitis
Sialopenia (>10%)
Sialorrhea (1–10%)
Xerostomia (>10%)
Hair
Hair – alopecia
Hair – hirsutism
Reactions
PRAZIQUANTEL
Trade names: Biltricide; Cisticid; Distocide; Flukacide; Kalcide;
Prazite; Tecprazin; Teniken
Indications: Helmintic infections
Category: Antihelmintic
Half-life: 0.8–1.5 hours
Clinically important, potentially hazardous interactions
with: dexamethasone
Reactions
Skin
Angioedema
(2006): Olson BG+, Pediatr Infect Dis J 25(5), 466 (with
ivermectin and albendazole)
Diaphoresis (1–10%)
Edema
(1995): Stelma FF+, Am J Trop Med Hyg 53, 167